ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-kind (WT) breast tumor cells and in cells lacking practical p53 both by yourself or in combination with tamoxifen, though the effectiveness of ABBV-744 was restric